VTVT
Price:
$13.87
Market Cap:
$36.23M
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approac...[Read more]
Industry
Biotechnology
IPO Date
2015-07-30
Stock Exchange
NASDAQ
Ticker
VTVT
According to vTv Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is -265.31%. This represents a change of 1.36% compared to the average of -18.15% of the last 4 quarters.
The mean historical ROE of vTv Therapeutics Inc. over the last ten years is 63.40%. The current -265.31% ROE has changed -518.45% with respect to the historical average. Over the past ten years (40 quarters), VTVT's ROE was at its highest in in the March 2022 quarter at 116.45%. The ROE was at its lowest in in the September 2024 quarter at -31.87%.
Average
63.40%
Median
26.62%
Minimum
7.24%
Maximum
233.45%
Discovering the peaks and valleys of vTv Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.55%
Maximum Annual ROE = 233.45%
Minimum Annual Increase = -75.38%
Minimum Annual ROE = 7.24%
Year | ROE | Change |
---|---|---|
2023 | 82.05% | -64.85% |
2022 | 233.45% | 28.24% |
2021 | 182.04% | 1.55% |
2020 | 11.02% | -75.38% |
2019 | 44.75% | 368.68% |
2018 | 9.55% | -10.66% |
2017 | 10.69% | -40.56% |
2016 | 17.98% | -49.02% |
2015 | 35.27% | 387.29% |
2014 | 7.24% | -54.40% |
The current ROE of vTv Therapeutics Inc. (VTVT) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
165.85%
5-year avg
110.66%
10-year avg
63.40%
vTv Therapeutics Inc.’s ROE is greater than Zura Bio Limited (-39.61%), less than Apexigen, Inc. (48.27%), greater than Phio Pharmaceuticals Corp. (-134.57%), less than eFFECTOR Therapeutics, Inc. (2.18%), greater than Immix Biopharma, Inc. (-102.10%), greater than Sigilon Therapeutics, Inc. (-74.73%), greater than NovaBay Pharmaceuticals, Inc. (-1030.19%), greater than InMed Pharmaceuticals Inc. (-16230.19%), greater than GeoVax Labs, Inc. (-809.91%), greater than Generation Bio Co. (-104.85%), greater than Kronos Bio, Inc. (-64.55%), greater than Erasca, Inc. (-42.26%), greater than C4 Therapeutics, Inc. (-42.45%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Allarity Therapeutics, Inc. (-328.22%), greater than NeuroBo Pharmaceuticals, Inc. (-189.12%), greater than Hillstream BioPharma, Inc. (-172.28%), greater than Virax Biolabs Group Limited (-115.10%), greater than Quoin Pharmaceuticals, Ltd. (-126.19%), greater than Pyxis Oncology, Inc. (-36.23%), less than Altamira Therapeutics Ltd. (783.37%), greater than Elevation Oncology, Inc. (-59.73%),
Company | ROE | Market cap |
---|---|---|
-39.61% | $151.48M | |
48.27% | $9.57M | |
-134.57% | $2.32M | |
2.18% | $941.00 | |
-102.10% | $59.97M | |
-74.73% | $56.22M | |
-1030.19% | $2.59M | |
-16230.19% | $3.35M | |
-809.91% | $21.33M | |
-104.85% | $71.47M | |
-64.55% | $57.32M | |
-42.26% | $726.61M | |
-42.45% | $273.18M | |
-26.83% | $2.80B | |
-328.22% | $4.50M | |
-189.12% | $20.33M | |
-172.28% | $4.17M | |
-115.10% | $7.47M | |
-126.19% | $2.45M | |
-36.23% | $95.15M | |
783.37% | $1.13M | |
-59.73% | $33.34M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like vTv Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like vTv Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is vTv Therapeutics Inc.'s ROE?
How is the ROE calculated for vTv Therapeutics Inc. (VTVT)?
What is the highest ROE for vTv Therapeutics Inc. (VTVT)?
What is the 3-year average ROE for vTv Therapeutics Inc. (VTVT)?
What is the 5-year average ROE for vTv Therapeutics Inc. (VTVT)?
How does the current ROE for vTv Therapeutics Inc. (VTVT) compare to its historical average?